<scp>FLT</scp>‐3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

FLT‐3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation

Published:2024-04-10 Issue:4 Volume:46 Page:741-743
ISSN:1751-5521
Container-title:International Journal of Laboratory Hematology
language:en
Short-container-title:Int J Lab Hematology

Author:

Xue Song¹^ORCID,Huang Wenqiu¹,Zhang Yongping¹,Liu Fuhong¹,Hao Qi¹,Hu Jiajun¹,Yuan Lei²,Wang Jingbo¹^ORCID

Affiliation:

1. Department of Hematology Aerospace Center Hospital Beijing China

2. Department of Hematology National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology Shenzhen Guangdong China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.14275

Reference10 articles.

1. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

2. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

3. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program

4. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment

5. Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia